Steven A. Kaplan, MD

Professor
Icahn School of Medicine at Mount Sinai

Steven A. Kaplan, M.D., FACS
Professor of Urology
Director, AUA Innovation Nexus


Steven Kaplan graduated from Mount Sinai School of Medicine in 1982 and was elected to the AOA Honor Society. Dr. Kaplan’s postgraduate training included residency in Urology at Columbia University and being an American Urologic Association Scholar between 1988 – 1990 that focused on identifying molecular markers that herald bladder and prostate dysfunction.

Dr. Kaplan was the Given Foundation Professor of Urology and Vice Chairman of the Department of Urology at Columbia University from 1998 – 2005. He is currently Tenured Professor of Urology and Director of The Men's Health Program at the Icahn School of Medicine at Mount Sinai and Director, American Urological Association Innovation Nexus

Dr. Kaplan is a serial entrepreneur and a founder of Medidata Solutions Inc., a publicly held corporation and one of the premier electronic data capture companies in the world; Medivizor, Inc., a medical informatics enterprise; Aspargo Labs, an innovative drug delivery system including the use of sildenafil spray for Erectile Dysfunction and Zeteo Health a bidirectional digital application using generative artificial intelligence to improve patient satisfaction and decrease priover inbox burden.

Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. He is a recognized authority on the study of benign diseases of the prostate and Men's Health. He has published more than 1300 articles, 190 abstracts, and has made over 350 presentations in more than 35 countries. He is the co - author of five books and is on the Editorial Board of Urology, Journal of Urology, and Urology Times. Dr. Kaplan has been a member of more than 30 professional organizations, been awarded 5 NIH grants and has received over 13 million dollars in research funding.

Disclosure information not submitted.

Presentation(s):

• 002IC - AUA BPH Management: Case Presentation Management to Enhance Safety and Efficacy

  Friday, April 28, 2023
  7:30 AM – 9:30 AM CST

• LUTS and Benign Prostatic Hyperplasia

  Friday, April 28, 2023
  9:45 AM – 10:10 AM CST

• MP13: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I

  Friday, April 28, 2023
  1:00 PM – 3:00 PM CST

• Working Together: Collaboration with Academic Institutions and International Partners

  Saturday, April 29, 2023
  10:46 AM – 10:55 AM CST

• Q&A with Session Speakers

  Saturday, April 29, 2023
  11:13 AM – 11:20 AM CST

• The Optilume BPH Catheter System and UroLift for BPH

  Saturday, April 29, 2023
  9:06 AM – 9:13 AM CST

• Round Table Discussion

  Saturday, April 29, 2023
  9:34 AM – 9:58 AM CST

• Reducing Health Disparities: Current Initiatives at the AUA Office of Research

  Saturday, April 29, 2023
  4:30 PM – 4:40 PM CST

• Q&A and Discussion with Session Speakers

  Saturday, April 29, 2023
  4:50 PM – 5:00 PM CST

• Emerging Trends in BPH Therapy

  Sunday, April 30, 2023
  8:10 AM – 8:35 AM CST

• BPH: Predicting the Future

  Sunday, April 30, 2023
  3:05 PM – 3:20 PM CST

• PD41-03: 12-Month Outcomes from a Randomized, Sham Controlled Study Evaluating a Novel Drug Coated Balloon for the Treatment of BPH

  Monday, May 1, 2023
  7:20 AM – 7:30 AM CST

• Enucleation for Everyone: Every Urologist Should Know It and Every Patient Should Get It vs With So Many Options, Who Needs It?

  Monday, May 1, 2023
  11:25 AM – 11:35 AM CST

• MP76-02: At 4 Years, Optilume BPH Has the Highest Sustained Improvement in Peak Flow (Qmax) of Any Minimally Invasive BPH Therapy

  Monday, May 1, 2023
  9:30 AM – 11:30 AM CST

• MP76-03: Procedural Complications Associated with MIST and Invasive Surgery Compared to Disease Progression with Medical Therapy

  Monday, May 1, 2023
  9:30 AM – 11:30 AM CST